Wednesday, 17 December 2025
4:17 PM
L17: AUTOIMMUNE DISEASE
1. CORE DEFINITION
Autoimmune disease is caused by failure of immunological self-tolerance, resulting in immune responses directed against self antigens, leading to tissue damage and organ dysfunction.
This concept was historically termed “horror autotoxicus” (Paul Ehrlich, ~1900).
2. IMMUNITY BALANCE: WHY AUTOIMMUNITY OCCURS
The immune system must balance:
Too little immunity Balanced immunity
Too much immunity
Immunodeficiency Pathogen clearance & tumor surveillance Autoimmune disease
Infections, tumors Normal health
Tissue damage, organ failure
Autoimmunity represents excess or misdirected immune activation
.
3. RELATIONSHIP TO IMMUNE TOLERANCE
Autoimmune disease arises when:
• Central tolerance fails (thymus / bone marrow)
• Peripheral tolerance fails (anergy, deletion, Tregs)
Key tolerance mechanisms involved:
• Clonal deletion
• Anergy
• Regulatory T cells (Tregs)
• Requirement for co-stimulation (B7–CD28)
Loss of these controls → persistent activation of self-reactive lymphocytes.
4. GENERAL PRINCIPLES OF AUTOIMMUNITY
Autoimmune diseases:
• Result from failure of self-tolerance
• Can be organ-specific or systemic
• Are chronic, progressive, and self-perpetuating
• Are driven by persistent self antigens
• Can be mediated by:
○ Autoantibodies
○ T cells (self-reactive)
○ Most commonly both
5. CENTRAL VS PERIPHERAL TOLERANCE FAILURE
Central tolerance failure
• Incomplete deletion of self-reactive T or B cells
• Defects in:
○ Thymic negative selection
○ AIRE-mediated antigen presentation
○ B-cell receptor editing
Peripheral tolerance failure
• Antigen recognition without proper suppression (absent suppression by Tregs)
• Breakdown of:
○ Anergy
○ Apoptosis
○ Treg-mediated suppression
6. ROLE OF CO-STIMULATION IN AUTOIMMUNITY
Context
Outcome
Antigen + co-stimulation (B7–CD28)
Immunity
Self-antigen without co-stimulation
Tolerance
Self-antigen with co-stimulation (Inappropriate) Autoimmunity
Inflammation and infection can convert tolerogenic self antigens into immunogenic targets.
7. GENETIC BASIS OF AUTOIMMUNE DISEASE
Evidence:
• Increased concordance in monozygotic twins
○ Type 1 diabetes: ~40% vs ~5% in dizygotic twins
• Polygenic inheritance
• Strong association with HLA alleles
○ e.g. HLA-B27 → Ankylosing spondylitis
7. GENETIC BASIS OF AUTOIMMUNE DISEASE
Evidence:
• Increased concordance in monozygotic twins
○ Type 1 diabetes: ~40% vs ~5% in dizygotic twins
• Polygenic inheritance
• Strong association with HLA alleles
○ e.g. HLA-B27 → Ankylosing spondylitis
Key immune genes implicated:
• HLA / MHC
• NOD2
• Insulin gene
• CD25 (IL-2 receptor)
• IL-23 receptor
8. ROLE OF INFECTION & ENVIRONMENT
Autoimmunity is often triggered by infection via:
(A) Molecular mimicry
• Pathogen antigens resemble self antigens
• Cross-reactive immune response
• Example:
○ Rheumatic fever following Streptococcus infection
(B) Bystander activation
• Infection-induced inflammation activates self-reactive lymphocytes (normally anergic)
• Damage exposes hidden self antigens
9. CLASSIFICATION OF AUTOIMMUNE DISEASES
A. Antibody-mediated autoimmune diseases
Key features:
• Transferable in plasma
• Caused by pathogenic autoantibodies
Disease
Target antigen
Autoimmune hemolytic anemia RBC membrane proteins
Pemphigus vulgaris
Desmosomal proteins (skin) → Blistering due to loss of cell adhesion
Myasthenia gravis
Acetylcholine receptor → muscle weakness and fatigue
Mechanisms:
• Complement activation
• Opsonisation
• Receptor blockade
B. T-cell-mediated autoimmune diseases
Key features:
• T cells present in lesions
• Strongly cytokine-driven inflammation
10. MULTIPLE SCLEROSIS
• T-cell mediated autoimmunity to myelin
• Leads to:
○ Demyelination
○ Impaired nerve conduction
○ Neurological deficits
• Likely involves:
○ Genetic susceptibility
○ Viral molecular mimicry
11. EPIDEMIOLOGY
• Affect 2–5% of population in developed countries
• Incidence increasing
• More common in women
• Peak onset: 20–40 years
• Chronic, disabling, major healthcare burden
12. DIAGNOSIS
Diagnosis may involve:
• Detection of autoantibodies
• Evidence of T-cell-mediated inflammation
• Clinical pattern (organ-specific vs systemic)
• Imaging and biopsy (for tissue damage)
13. THERAPEUTIC STRATEGIES
General approaches:
Anti-inflammatory drugs
• Corticosteroids
• NSAIDs
Immunosuppressants
• Cyclosporine
• Methotrexate
Antibody-based therapies
• Anti-CD20 (Rituximab) → B-cell depletion
• Anti-TNFα (Infliximab)
Plasmapheresis
• Removes circulating autoantibodies and immune complexes
Disease-specific therapy
• Tailored to the affected organ/system